Best overall response by MYD88/CXCR4 genotype. For efficacy-evaluable patients with tumors harboring the MYD88^L265P mutation, best response is reported separately for those with CXCR4^WT disease and those with an accompanying CXCR4^WHIM mutation. No genotype data were available for 8 patients. The CXCR4 genotype is unknown (CXCR4^UNK) for an additional 7 patients with MYD88^L265P disease.